BioLargo Accelerates Commercialization with MedTech Rollout and PFAS Filtration Deployment

BioLargo US09065A1007

BioLargo reports forward momentum across its core businesses, highlighting a concrete MedTech push and a progressive environmental clean-up initiative. The company cites a first stocking order for a new wound irrigation solution from its Clyra Medical Technologies unit, the installation of an AEC PFAS filtration system at a New Jersey municipal water facility, and advancing partnerships tied to Cellinity battery manufacturing. These milestones are positioned to shape the fiscal year 2026, with management counting on tangible revenue contributions in the near term.

• Clyra Medical Technologies receives an initial stocking order for ViaCLYR™ wound irrigation solution.
• An AEC PFAS filtration system is installed at a municipal water facility in New Jersey for a one-year testing period.
• Progress is reported on partnerships for Cellinity battery factory development.

Clyra Medical Technologies, BioLargo’s subsidiary, secured its first stocking order for the ViaCLYR™ wound irrigation solution earlier this month. The company’s distributor, Advanced Solution, is preparing the market launch, which is slated for the current first quarter. Management expects that Clyra will contribute meaningfully to commercial revenue for the first time in 2026.

Validation of Environmental Technology

A key focus is the AEC technology designed to filter PFAS chemicals. At the end of January, the system was installed at the Lake Stockholm municipal water facility in New Jersey. In collaboration with the regulatory authorities, a twelve-month monitoring phase has begun, including regular testing. Data gathered over this period will be critical to satisfy regulatory requirements and to demonstrate the system’s reliability for ongoing municipal use.

Battery Technology and Outlook

The company is also advancing Cellinity’s battery technology for large-scale energy storage. Investors are watching closely for updates on potential public-private partnerships aimed at building production facilities.

Outlook and Financials

BioLargo plans to release its next financial figures in the spring. Market chatter varies on timing: some sources anticipate a report by late March or early April, while others point to mid‑May 2026. The most recent financial data available were published on November 14 of the previous year.